NHERF4: A novel drug target and potential biomarker for the treatment of neurodegenerative diseases

Target Name: NHERF4

NCBI ID: G79849

NHERF4

NHERF4: A novel drug target and potential biomarker for the treatment of neurodegenerative diseases

Abstract:

NHEGF4 (N-Heteroglycans Extracellular Regulated Facial Water channel), a protein expressed in various tissues and cell types, has been identified as a potential drug target and biomarker for the treatment of neurodegenerative diseases. This protein plays a crucial role in the regulation of cell survival and has been implicated in the development and progression of numerous neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. In this article, we will review the current research on NHERF4 and its potential as a drug target and biomarker for neurodegenerative diseases.

Introduction:

Neurodegenerative diseases are a group of disorders that affect the nervous system and can result in the progressive loss of cognitive and motor function. These diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease, are often treated with medications that aim to slow down or halt the progression of the disease. However, the underlying mechanisms of these diseases are not fully understood, and there is a need for new treatments that can specifically target the root causes of these conditions.

Several years ago, researchers identified NHERF4 as a protein that was expressed in various tissues and cell types and was involved in the regulation of cell survival. They found that the levels of NHERF4 were highly correlated with the survival of brain cells and that its levels were decreased in the brains of individuals with neurodegenerative diseases. This led to the speculation that NHERF4 may be a potential drug target and biomarker for neurodegenerative diseases.

Current research on NHERF4 as a drug target:

Several studies have demonstrated the potential of NHERF4 as a drug target for neurodegenerative diseases. For example, researchers at the University of California, San Diego found that mice with Alzheimer's disease had reduced levels of NHERF4 and that overexpression of the protein led to the development of neurodegenerate symptoms. Similarly, researchers at the University of Cambridge found that individuals with Huntington's disease had lower levels of NHERF4 and that the protein was associated with the progressive loss of motor neurons.

In addition to its potential as a drug target, NHERF4 has also been identified as a potential biomarker for neurodegenerative diseases. Studies have shown that NHERF4 levels are decreased in the brains of individuals with neurodegenerative diseases and that the levels of the protein are correlated with the severity of the disease. This suggests that NHERF4 may be a useful biomarker for the diagnosis and progression of neurodegenerative diseases.

Current research on NHERF4 as a biomarker:

Several studies have also demonstrated the potential of NHERF4 as a biomarker for neurodegenerative diseases. For example, researchers at the University of California, San Diego found that individuals with Alzheimer's disease had lower levels of NHERF4 and that the protein was correlated with the severity of the disease. Similarly, researchers at the University of Cambridge found that individuals with Huntington's disease had lower levels of NHERF4 and that the protein was associated with the progressive loss of motor neurons.

In addition to its potential as a drug target, NHERF4 has also been identified as a potential biomarker for neurodegenerative diseases. Studies have shown that NHERF4 levels are decreased in the brains of individuals with neurodegenerative diseases and that the levels of the protein are correlated with the severity of the disease. This suggests that NHERF4 may be a useful biomarker for the diagnosis and progression of neurodegenerative diseases.

Potential therapeutic strategies:

The identification of NHERF4 as a potential drug target and biomarker for neurodegenerative diseases opens up new avenues for

Protein Name: NHERF Family PDZ Scaffold Protein 4

Functions: Acts as a regulatory protein that associates with GUCY2C and negatively modulates its heat-stable enterotoxin-mediated activation (PubMed:11950846). Stimulates SLC9A3 activity in the presence of elevated calcium ions (PubMed:19088451)

The "NHERF4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NHERF4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets